This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Elan Announces Publication Of EGM Circular In Respect Of Proposed Demerger

Elan Corporation, plc (NYSE: ELN) today announced the publication and filing of a circular to shareholders convening an extraordinary general meeting (“EGM”) to be held in the Davenport Hotel, 8/10 Merrion Street Lower, Dublin 2, Ireland at 10.00 a.m. on Wednesday, December 12, 2012 at which a resolution in connection with the proposed demerger of Elan’s Neotope business (now referred to as the Prothena Business), originally announced on August 13, 2012, will be considered and voted on.

As previously announced, and assuming the necessary preconditions are fulfilled, including an affirmative vote of the Elan shareholders at the EGM, the Prothena business which comprises a substantial portion of Elan’s drug discovery business platform, will be separated into another company by way of a demerger. This company, previously named Neotope Corporation plc, but now named Prothena Corporation plc (Prothena), will be a new publicly traded company incorporated in Ireland.

Under the demerger, Elan will transfer the Prothena Business to Prothena in exchange for Prothena issuing directly to the holders of Elan ordinary shareholders and American Depositary Shares, on a pro rata basis, Prothena shares, representing 99.99% of Prothena’s outstanding shares. Immediately after the demerger (and conditional on prior completion of the demerger) a wholly owned subsidiary of Elan will subscribe $26 million and receive Prothena shares representing 18% of the total outstanding ordinary shares of Prothena (as calculated immediately following the subscription by Elan). The remaining 0.01% of Prothena’s outstanding shares, which were issued to the original incorporators of Prothena will then be redeemed and cancelled. Accordingly, after completion of the transaction, Elan shareholders will directly and indirectly own 100% of the Prothena Business by virtue of their direct ownership of 82% of Prothena’s outstanding shares and indirect ownership of 18% of Prothena’s outstanding shares. Additionally, in connection with the reorganization of the Prothena Business, which preceeds the demerger, Elan is making a cash investment of $99 million in the subsidiaries holding the Prothena Business.

It is intended that application will be made for the Prothena shares to be admitted to trading on the NASDAQ Global Market, with such admission expected to occur immediately after completion of the demerger. Prothena will not be conducting any offering of its shares as part of such admission and its shares will not be admitted to trading on any market other than the NASDAQ Global Market.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,132.96 +52.82 0.29%
S&P 500 2,120.86 +3.17 0.15%
NASDAQ 5,101.3720 +9.2870 0.18%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs